A recent study in the European Heart Journal highlights the benefits of starting disease-modifying therapies in community-based patients with suspected heart failure. For patients with elevated NT-proBNP, early treatment with SGLT2 inhibitors and MRAs before diagnostic echocardiography significantly reduces the 12-month risk of hospitalization or death.